Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 18, 2026
Why Is Profusa, Inc. (PFSA) Stock Up +195.58% Today?

Why Is Profusa, Inc. (PFSA) Stock Up +195.58% Today?

Key Takeaways

  • Shares of Profusa, Inc. were up 195.58% in morning trading Tuesday, last at $13.39, compared with Monday's close of $4.53.
  • Primary catalyst: The company's previously announced 1-for-4 reverse stock split took effect on August 18, 2026.
  • Secondary drivers: An extremely reduced share count, event-driven speculation, and the company's recent option agreement to acquire diagnostics company G3 Vision Labs.
  • Market context: The move is company-specific rather than a broad market or sector repricing.
  • What traders are watching next: Profusa's upcoming quarterly report, estimated for August 21, and progress on the G3 Vision Labs option and related financing.

Opening Summary

Profusa, Inc. (PFSA) is a Berkeley, California-based digital health and biosensor company developing tissue-integrated sensors for continuous biochemical monitoring. In morning trading Tuesday, shares of the micro-cap medical technology company were up 195.58%, changing hands at $13.39 as of 10:31 a.m. ET, compared with Monday's closing price of $4.53.

The sharp increase reflects the effectiveness of a 1-for-4 reverse stock split, which mechanically re-prices the stock across a smaller number of shares outstanding. While the quoted price is significantly higher, the move is primarily a corporate-action repricing rather than a proportional increase in the company's market value.

1-for-4 Reverse Stock Split Takes Effect

Profusa, Inc. (PFSA) announced that its previously approved 1-for-4 reverse stock split became effective August 18, 2026. The split consolidates every four shares of common stock into one share, leaving the par value unchanged at $0.0001 per share. Fractional shares are not being issued; cash is provided in lieu.

As a result, the company's outstanding share count is reduced from approximately 2,422,906 shares to approximately 605,726 shares, while authorized shares remain at 601 million. This is the third reverse split for PFSA in 2026, following a 1-for-75 split in February and a 1-for-25 split in July. Because the higher quoted price is spread across fewer shares, the headline percentage move overstates any change in shareholder value.

Speculative, Low-Float Trading Amplifies the Move

The reduction in shares outstanding has created an exceptionally low-float trading environment for PFSA. With fewer shares available for trading, order flow can produce outsized percentage swings, and the stock has been attracting event-driven and speculative interest around the split. Trading volume has been elevated relative to the company's typical activity, consistent with a volatile, corporate-action-driven tape rather than a fundamental repricing.

G3 Vision Labs Option Provides Fundamental Backdrop

Beyond the reverse split, PFSA has been in focus following its July 31 announcement of an option agreement to acquire G3 Vision Labs and its diagnostics subsidiaries. G3 reported estimated 2025 net revenues of approximately $111 million based on unaudited management information. The option is subject to conditions including at least $30 million in financing, debt resolution, and stockholder approval.

The potential acquisition would mark a strategic shift for the biosensor company toward a commercial-stage diagnostics platform with CLIA-certified laboratories. While the G3 agreement is not the immediate trigger for Tuesday's price action, it has contributed to elevated attention on the stock and supports the broader speculative narrative around the company's transformation.

Market Context and Trading Activity

Tuesday's move in PFSA is company-specific. There is no clear sector-wide catalyst or broad market event driving the repricing, and the move is not aligned with a major healthcare or medical-device index trend. The action is consistent with a micro-cap stock undergoing a reverse split, where technical levels and traditional valuation metrics are less relevant than share-count mechanics and liquidity conditions.

What Comes Next for PFSA

Traders are now focused on Profusa's next quarterly report, estimated for August 21 before the market open, which could provide updated financial detail and commentary on the company's strategic direction. Attention also remains on the G3 Vision Labs option, including whether the company can satisfy the financing and approval conditions required to exercise it.

Risks include continued volatility from the reduced share count, uncertainty around the G3 transaction, potential dilution from convertible preferred stock, and the company's history of multiple reverse splits. While the quoted share price has risen sharply, the underlying business and financing milestones remain the key fundamental considerations.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of AI trading bots that are currently among the strongest performers under prevailing market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with strategies that vary by timeframe, trading style, performance metrics, and traded symbols. Traders interested in data-driven tools can review the page to see which AI-driven strategies are currently leading.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PFSA

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


PFSA in +9.92% Uptrend, advancing for three consecutive days on September 08, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PFSA advanced for three days, in of 55 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Bearish Trend Analysis

The 10-day RSI Indicator for PFSA moved out of overbought territory on August 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on August 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PFSA as a result. In of 49 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for PFSA turned negative on August 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .

PFSA moved below its 50-day moving average on August 20, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for PFSA crossed bearishly below the 50-day moving average on August 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFSA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PFSA broke above its upper Bollinger Band on August 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PFSA entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (10.671). P/E Ratio (0.000) is within average values for comparable stocks, (67.760). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.658). PFSA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (0.000) is also within normal values, averaging (35.853).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PFSA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFSA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 5.49B. The market cap for tickers in the group ranges from 1.86K to 178.85B. ABT holds the highest valuation in this group at 178.85B. The lowest valued company is CSAY at 1.86K.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -5%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -7%. TNON experienced the highest price growth at 41%, while CTSO experienced the biggest fall at -95%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was 61%. For the same stocks of the Industry, the average monthly volume growth was -8% and the average quarterly volume growth was 12%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 75
Price Growth Rating: 61
SMR Rating: 89
Profit Risk Rating: 95
Seasonality Score: -21 (-100 ... +100)
View a ticker or compare two or three
PFSA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalNursingServices

Profile
Details
Industry
N/A
Address
626 Bancroft Way
Phone
+1 925 997-6925
Employees
N/A
Web
https://www.profusa.com
Interact to see
Advertisement
HIMS shares surged approximately +43.85% in premarket trading on Monday, March 9, 2026, rising from a prior close of $15.74 to around $22.80. Primary catalyst: Novo Nordisk officially ended its patent infringement lawsuit against Hims & Hers and announced a landmark partnership to distribute branded Wegovy through the Hims platform at $599/month.
XENE shares surged approximately +45.93% in premarket trading on March 9, 2026, one of the largest single-session moves in the company's history. The primary catalyst: Xenon announced positive topline Phase 3 X-TOLE2 results for its lead drug candidate azetukalner in focal onset seizures (FOS), meeting the primary endpoint with overwhelming statistical significance.
Shares of OLMA dropped approximately 41% in Monday's session, one of the steepest single-day declines in the company's history. The primary catalyst was Roche's Phase 3 persevERA trial failure — a late-stage study of giredestrant, a closely competing selective estrogen receptor degrader (SERD), which missed its primary endpoint of statistically significant improvement in progression-free survival.
RLMD shares surged approximately +40% at the open on March 9, 2026, rising from a prior close of $4.45 to approximately $6.23, driven by a major clinical trial readout. The primary catalyst was the announcement of 12-month interim data from the Phase 2 trial of NDV-01, Relmada's lead oncology candidate, in patients with high-risk non-muscle invasive bladder cancer (NMIBC) — results that significantly exceeded historical benchmarks.
CRCL surged +8.66% on Monday, March 9, 2026, rising from a prior close of $101.94 to trade at $110.77 intraday. The primary catalyst is a landmark stablecoin milestone: Circle's USDC overtook Tether as the dominant stablecoin by transfer volume, accounting for approximately 70% of all stablecoin transfer activity as total stablecoin transfers hit $1.8 trillion in February.
Carnival Corporation (CCL) shares fell approximately -7.60% in Monday's session, dropping from a Friday close of $25.79 to around $23.83. The primary catalyst is a broad market sell-off driven by intensifying recession fears, with the S&P 500 and consumer discretionary names bearing the brunt of the pressure.
Shares of Bloom Energy (BE) are surging approximately +10.30% in Monday's session, rebounding sharply from a steep -15.50% selloff on Friday, March 6, 2026. Friday's decline was triggered by an Oracle-OpenAI data center project update that spooked energy infrastructure investors; Monday's move reflects aggressive dip-buying and a sentiment reset.
IGV has rallied about 8–9% in the last 6 trading days, while SOXX has dropped about 8%, giving software a +16.6 percentage‑point edge—the largest 6‑day software‑over‑semi outperformance ever.[barchart]​ This comes right after software lagged semis by almost −15 percentage points into late January, the widest gap since 2008, and as hedge‑fund short exposure to U.S. software and services hit a record ~3.8% of market cap.
Crude’s explosive war‑driven spike faded on March 9 because the market suddenly started to price less extreme, shorter‑lived supply risk and more policy intervention, not a multi‑month shortage. WTI, which had briefly traded above 115–120 dollars on Iran‑war headlines and Strait of Hormuz fears, slid back toward the high‑80s as traders digested G7 reserve‑release talk, Trump’s comments about a “brief” war, and the reality that prices had run far ahead of fundamentals.
Shares of ARQ plunged approximately 27.50% in premarket trading on March 10, 2026, from a prior close of $3.20 to roughly $2.32. The primary catalyst was a deeply disappointing Q4 2025 earnings report, which revealed a net loss of $50.0 million for the quarter versus a net loss of $1.3 million in Q4 2024.
RAIL shares fell approximately 15% in premarket trading on March 10, 2026, following a steep after-hours reaction to disappointing Q4 2025 earnings results released after the close on March 9. The primary catalyst was a significant revenue miss: Q4 revenue came in at $125.6 million, well below consensus estimates near $144–$160 million, representing an 8.8% year-over-year decline.
ZVRA shares surged approximately +17.86% on March 10, 2026, driven by a blockbuster Q4 and full-year 2025 earnings report released before the market open. Primary catalyst: Q4 2025 EPS of $0.19 crushed the consensus estimate of $0.05 — a 280% beat — while revenue of $34.1 million exceeded forecasts by 21.57%.
LITE surged +14.73% on Monday, March 9, 2026, closing at $640.69 versus a prior close of $558.44 on March 6. The primary catalyst was the landmark $2 billion strategic investment by NVIDIA announced March 2, with the market continuing to price in its full implications following a brief post-announcement pullback.
Shares of BNTX fell approximately 22% on Tuesday, March 10, 2026, following a dual shock of disappointing full-year guidance and a surprise leadership upheaval. The primary catalyst was BioNTech's Q4 2025 earnings report, which included a 2026 revenue outlook of €2.0–€2.3 billion — well below analyst consensus and signaling continued pressure from declining COVID-19 vaccine demand.
CNC shares fell approximately 10% during Tuesday's session, extending a prolonged selloff in the managed care sector. The primary catalyst is intensifying investor concern over federal Medicaid and ACA funding cuts tied to the "One Big Beautiful Bill Act" (OBBBA), which threatens to shrink the government-sponsored insurance pools that Centene depends on for the majority of its revenue.
Technology recently peaked near 35% of the S&P 500 and has slipped over the last year, while Energy plus Materials remain near historically low combined weight at roughly 6%, which suggests the gap is still unusually wide.
Average daily equity purchases by retail investors on S&P 500 down days in 2026 are at the highest level on record, running about 100% above the peak intensity seen during the 2021 meme‑stock boom.
Over the past two weeks, PLTR has climbed from roughly the high‑130s to the mid‑150s, a gain of about 12–14%, with a series of strong up days between March 2 and March 6.
AVAV shares dropped approximately 10% in premarket trading on March 11, 2026, following a disappointing Q3 fiscal 2026 earnings report released after the prior session's close. Q3 revenue of $408.0 million came in far below analyst consensus of approximately $475–$488 million, representing a massive top-line miss.
KOS shares are down approximately 20% in premarket trading on March 11, 2026, having shed roughly 20.31% across the last two sessions (Tuesday close and premarket Wednesday). The primary catalyst is Kosmos Energy's announcement of a massive $185.25 million public equity offering priced at $1.90 per share — a steep discount to recent trading levels.